Table of Contents Author Guidelines Submit a Manuscript
Pulmonary Medicine
Volume 2011, Article ID 751982, 5 pages
http://dx.doi.org/10.1155/2011/751982
Review Article

The Role of Macrolides in Noncystic Fibrosis Bronchiectasis

Department of Pediatrics, Federal University of Minas Gerais, Brazil

Received 16 June 2011; Revised 23 August 2011; Accepted 24 August 2011

Academic Editor: Charlie Strange

Copyright © 2011 Bruna de Campos Guimarães e Figueiredo and Cássio da Cunha Ibiapina. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. The present study aims at reviewing the main publications on the use of macrolides as immunomodulators in patients with noncystic fibrosis bronchiectasis. Source of Data. The Medline database was our source of data for this research carried out until June 2011, using the key words: macrolides and bronchiectasis, while searching for original articles and reviews. Summary of Data. Seven clinical studies that evaluated the action of the macrolides in patients with bronchiectasis were found. There was the sputum volume, reduction in pulmonary exacerbation frequency, and in the use of antimicrobial treatment, in addition to pulmonary function improvement. Conclusions. Anti-inflammatory action and immunomodulatory effects can be attributed to macrolides when administered in low doses and on the long term. This use has been well established both in diffuse panbronchiolitis and in cystic fibrosis. Evidence indicates possible benefits in bronchiectasis. Future studies are needed, though, to establish the ideal dose and treatment duration and to understand the implications in the generation of microbial resistance.